Bostick-Bruton F - Search Results

1

Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures.

Fisher RI, Bostick-Bruton F, Sauder DN, Scala G, Diehl V. Fisher RI, et al. J Immunol. 1983 Jun;130(6):2666-70. J Immunol. 1983. PMID: 6222113

2

Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses.

Fisher RI, Bates SE, Bostick-Bruton F, Tuteja N, Diehl V. Fisher RI, et al. J Immunol. 1984 May;132(5):2672-7. J Immunol. 1984. PMID: 6609204

3

Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide.

Fisher RI, Bostick-Bruton F. Fisher RI, et al. J Immunol. 1982 Oct;129(4):1770-4. J Immunol. 1982. PMID: 6980949

4

Deficient helper cell function as a cause of diminished pokeweed mitogen blastogenic responses in patients with non-Hodgkin's lymphomas.

Silver BA, Bostick-Bruton FW, Neckers L, Fisher RI. Silver BA, et al. Cancer. 1984 Dec 15;54(12):2936-42. doi: 10.1002/1097-0142(19841215)54:12<2936::aid-cncr2820541220>3.0.co;2-v. Cancer. 1984. PMID: 6238671

5

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM. Reed E, et al. Cancer Res. 1993 Aug 15;53(16):3694-9. Cancer Res. 1993. PMID: 8339278 Clinical Trial.

6

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. Dabholkar M, et al. J Natl Cancer Inst. 1992 Oct 7;84(19):1512-7. doi: 10.1093/jnci/84.19.1512. J Natl Cancer Inst. 1992. PMID: 1433335

7

Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro.

Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM, Reed E. Dabholkar M, et al. Environ Health Perspect. 1992 Nov;98:53-9. doi: 10.1289/ehp.929853. Environ Health Perspect. 1992. PMID: 1486863 Free PMC article.

8

Suramin in advanced platinum-resistant ovarian cancer.

Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE. Reed E, et al. Eur J Cancer. 1992;28A(4-5):864-6. doi: 10.1016/0959-8049(92)90135-o. Eur J Cancer. 1992. PMID: 1524910 Clinical Trial.

9

Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.

Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E. Parker RJ, et al. J Natl Cancer Inst Monogr. 1993;(15):83-8. J Natl Cancer Inst Monogr. 1993. PMID: 7912534

10

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Dabholkar M, et al. J Clin Invest. 1994 Aug;94(2):703-8. doi: 10.1172/JCI117388. J Clin Invest. 1994. PMID: 8040325 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters